Novel Cytotoxic Compounds
Researchers at Wake Forest University (WFU), the National Cancer Institute (NCI) and the University of New Hampshire have developed and a novel class of anti-tumor compounds that have been tested in vivo against human tumor cells.
Unpublished efficacy, pharmacokinetic and toxicity tests have been performed in vivo. Hollow fiber animal studies with viable human tumor cells inserted into mice were performed by the NCI’s Rapid Access to Intervention Development (RAID) program. Twelve different human tumor cell lines were implanted into living mice both intraperitoneally (IP) and subcutaneously and allowed to form viable cell masses. The compound was administered IP at two dose levels.
¨ IP: Over ½ of the human tumor cell lines were reduced by 50% or more
¨ Three human tumor cell Lines were Completely killed In Vivo: lung, colon and glioma
Pharmacokinetic data includes plasma absorption and clearance after subcutaneous, intraperitoneal and intravenous administration. A toxicity range-finding protocol has been preformed resulting in an optimal animal model for further toxicity testing.
In vitro assays have also been performed. Efficacy was demonstrated against human and mouse bladder cancer cell lines with an IC50 of 4.6 micromol/liter.
Publications detailing the in vitro data are available upon request. Complete in vivo data is available under an appropriate confidentiality agreement.
Covered by United States Patent 6,589,966, “Cytotoxic metal chelators and methods for making and using same”.